SEROLOGICAL AUTOANTIBODIES AS BIOMARKER FOR COLORECTAL CANCER

摘要

The present invention pertains to a new method for the diagnosis, prognosis, stratification and/or monitoring of a therapy, of colorectal cancer in a patient. The method is based on the determination of the level or concentration of one or more autoantibodies specific for a tumor associated antigen selected from TP53, IMPDH2, MAGEA4, RPL13, MDM2, CTAG1, RPH3AL, ANXA4, MTDH, TPM3_isol, ERBB2_C_term, IGF2BP1, MIA, DDX53, HMGN3, CALU, KLK3_isol, REG3A, CTAG2, ERBB2_N_term, and MAGEA3. The new serological antibody marker panel of the invention allows diagnosing and even stratifying colorectal cancer diseases. Furthermore provided are diagnostic kits for performing the non-invasive methods of the invention.